✦ LIBER ✦

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

✍ Scribed by Wasaburo Koizumi; Hiroyuki Narahara; Takuo Hara; Akinori Takagane; Toshikazu Akiya; Masakazu Takagi; Kosei Miyashita; Takashi Nishizaki; Osamu Kobayashi; Wataru Takiyama; Yasushi Toh; Takashi Nagaie; Seiichi Takagi; Yoshitaka Yamamura; Kimihiko Yanaoka; Hiroyuki Orita; Masahiro Takeuchi

Book ID: 117784627
Publisher: The Lancet
Year: 2008
Tongue: English
Weight: 155 KB
Volume: 9
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(08)70035-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Biweekly irinotecan plus cisplatin versu

Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: A randomised phase III trial (TCOG GI-0801/BIRIP trial)

✍ Higuchi, Katsuhiko; Tanabe, Satoshi; Shimada, Ken; Hosaka, Hisashi; Sasaki, Eisa 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 750 KB

3516 POSTER Report of safety analysis in

3516 POSTER Report of safety analysis in a randomized phase III study comparing S-1 alone with S-1 plus CDDP in advanced gastric cancer (The SPIRITS trial. TS-1 Advanced Gastric Cancer Clinical Trial Group)

✍ T. Hara; W. Koizumi; H. Narahara; A. Takagane; T. Akiya; M. Takagi; K. Miyashita 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Three-weekly S-1 plus cisplatin chemothe

Three-weekly S-1 plus cisplatin chemotherapy as first-line treatment for advanced gastric cancer

✍ In Sil Choi; Keun-Wook Lee; Ki Hwan Kim; Yu Jung Kim; Jee Hyun Kim; Jong Seok Le 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 212 KB

Clinical development of S-1 plus cisplat

Clinical development of S-1 plus cisplatin therapy as first-line treatment for advanced gastric cancer

✍ Wasaburo Koizumi 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 171 KB

A randomized phase II trial to elucidate

A randomized phase II trial to elucidate the efficacy of capecitabine plus cisplatin (XP) and S-1 plus cisplatin (SP) as a first-line treatment for advanced gastric cancer: XP ascertainment vs. SP randomized PII trial (XParTS II)

✍ Akira Tsuburaya, Satoshi Morita, Yasuhiro Kodera, Michiya Kobayashi, Kohei Shita 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 157 KB

A randomized phase II study comparing S-

A randomized phase II study comparing S-1 plus weekly split-dose cisplatin with S-1 plus standard-dose cisplatin as first-line chemotherapy for advanced gastric cancer

✍ Toshikazu Moriwaki, Shinji Hirai, Shuichi Hironaka, Kenji Amagai, Atsuko Soeda, 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 289 KB